Genmab — Januar 2021
-
Opbrud på vigtigt Genmab-marked: Partner er kommet flyvende fra start
Genmabs schweiziske partner Novartis er kommet stærkt fra start med lanceringen af sklerosemidlet Kesimpta, vurderer storbanken Morgan Stanley. Midlet imponerer også Danske Bank.
Finans (finans.dk)
-
Dejligt med positive nyheder.
-
Janssen collaborating now on this new small ATRA / Dara trial https://www.clinicaltrials.gov/ct2/show/NCT04700176?term=ATRA+AND+daratumumab&draw=2&rank=2
-
Skal da lige love for, at der blev hældt af i lukkeauktionen!
-
Genmab/JPMorgan: Kursmålet løftes med over 33 pct.
Den amerikanske storbank JPMorgan har haft Genmab-aktien til eftersyn og løfter sit kursmål til 2600 kr. fra 1950 kr. Det berettiger stadig til anbefalingen "overvægt", viser data fra Bloomberg News.
Finans (finans.dk)
-
https://finance.yahoo.com/news/biontech-publishes-data-novel-mrna-191500610.html Biontech kan som vi ved mere vacciner. Spændende selskab.
-
-
God morgen

-
God morgen.

-
Fredagens danske avisuddrag med Danske Bank, Bitcoin og Mærsk: https://www.proinvestor.com/investornyt/670927/fredagens-danske-avisuddrag-med-danske-bank-bitcoin-og-maersk
-
GENMAB A/S <GMAB.CO>: JEFFERIES RAISES TARGET PRICE TO DKK 2900 FROM DKK 2800 - RTRS | News Wires | Refinitiv Eikon
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind